Loading clinical trials...

Predicting Pathological Complete Response of Rectal Cancer With Magnetic Resonance(MR) Radiomics | Clinical Trials | Clareo Health

COMPLETED

Predicting Pathological Complete Response of Rectal Cancer With Magnetic Resonance(MR) Radiomics

Predicting Pathological Complete Response of Rectal Cancer to Neoadjuvant Chemoradiotherapy With MR Radiomics Method

NCT03238885•Sun Ying-Shi

View on ClinicalTrials.gov

Summary

This study plans to construct a MR radiomics model for predicting pathological complete response(pCR) to neoadjuvant chemoradiotherapy(CRT) in locally advanced rectal cancer(LARC) patients.

Detailed Description

We propose to develop and validate a radiomics model for individualized pCR evaluation after CRT in patients with LARC. We plan to use both pre- and post-CRT MRI data to construct the predictive radiomics model for evaluating if LARC patients achieve pCR after CRT. The ultimate aim is to select appropriate LARC patients for omission of surgery.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•pathologically proved rectal cancer
•locally advanced rectal cancer (≥T3 or N+)
•a distance less than 12cm between the lower edge of tumor and the anal margin
•no evidence of distant metastases
•no prior anti-cancer therapy before treatment
•scheduled to receive preoperative CRT

Exclusion Criteria

•history or concurrent of other malignancy
•incomplete preoperative CRT
•failed to receive surgery or unavailable pCR assessment
•poor quality of MR images for measurement
•patient quit

Locations (1)

Beijing Cancer Hospital

Beijing, Beijing Municipality, China

Key Dates

Start Date

March 1, 2013

Primary Completion Date

December 18, 2018

Completion Date

January 21, 2019

Last Updated

February 4, 2019

Enrollment

538

ACTUAL participants

Conditions

Locally Advanced Rectal Cancer

Interventions

pelvic MR examination

DIAGNOSTIC_TEST

SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer

NCT05412082

Locally Advanced Rectal Cancer

View study

RECRUITINGPHASE2

Node-sparing Radiotherapy Combined with Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer

NCT06204094

Locally Advanced Rectal Cancer

View study

RECRUITINGPHASE2

Consolidation Versus Induction Chemotherapy in Total Neoadjuvant Therapy of Rectal Cancer With High Risk for Recurrence

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 4, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Predicting Pathological Complete Response of Rectal Cancer With Magnetic Resonance(MR) Radiomics

Inclusion Criteria

Exclusion Criteria

SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer

Node-sparing Radiotherapy Combined with Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer

Consolidation Versus Induction Chemotherapy in Total Neoadjuvant Therapy of Rectal Cancer With High Risk for Recurrence

A Pospective, Single-arm, Multicenter Clinical Trial Evaluating Preoperative Neoadjuvant mFOLFOX6 Chemotherapy in Combination With PD1 Monoclonal Antibody in MSS/pMMR Locally Advanced Rectal Cancer

Intraoperative Electron Radiotherapy in Rectal Cancer - A Feasibility Trial

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer